Tags : KSQ Therapeutics

PharmaShots Weekly Snapshot (October 14-18, 2019)

1. Johnson & Johnson Initiates Voluntarily Recall of a Single Lot of its Baby Powder in the US Published: Oct 18, 2019 | Tags: JnJ, Initiates, Voluntarily, Recall, Baby Powder, US 2. AbbVie’s Rinvoq (Upadacitinib) Receives CHMP Positive Opinion to Treat Moderate to Severe Active Rheumatoid Arthritis Published: Oct 18, 2019 | Tags: AbbVie, Rinvoq, Upadacitinib, Receives, […]Read More

CRISPR Therapeutics and KSQ Therapeutics Cross Licenses their IP Rights

Shots: CRISPR to gain access to KSQ intellectual property (IP) for editing certain novel gene targets in its allogeneic oncology cell therapy programs while KSQ will get access to CRISPR’ IP for its autologous cell therapies including its existing eTIL cell franchise The agreement allows KSQ to leverage CRISPR’s editing technology in its eTIL programs, […]Read More